You just read:

Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome

News provided by

Neurocrine Biosciences, Inc.

Dec 16, 2015, 04:05 ET